Spots Global Cancer Trial Database for on 01910.na
Every month we try and update this database with for on 01910.na cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | NCT01538563 | Solid Tumors Advanced Cancer Cancer Neoplasms | rigosertib sodi... | 18 Years - | Traws Pharma, Inc. | |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | NCT01584531 | Myelodysplastic... MDS Trisomy 8 | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | NCT00906334 | Myelodysplastic... | ON 01910.Na ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer | NCT01360853 | Metastatic Panc... | ON 01910.Na Gemcitabine Gemcitabine | 18 Years - | Traws Pharma, Inc. | |
| Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | NCT00854945 | Myelodysplastic... Acute Myeloid L... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer | NCT01538537 | Advanced Cancer Solid Tumors Cancer Neoplasms | rigosertib sodi... | 18 Years - | Traws Pharma, Inc. | |
| Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome | NCT01048619 | Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors | NCT01165905 | Solid Tumor | ON 01910.Na Gemcitabine | 18 Years - | Traws Pharma, Inc. | |
| Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | NCT00856791 | Ovarian Cancer | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts | NCT01241500 | Myelodysplastic... MDS RAEB Chronic Myelomo... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | NCT01538563 | Solid Tumors Advanced Cancer Cancer Neoplasms | rigosertib sodi... | 18 Years - | Traws Pharma, Inc. | |
| Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin | NCT00861328 | Advanced Solid ... | ON 01910.Na and... ON 01910.Na and... | 18 Years - | Traws Pharma, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
